ArticleNature cancer2021

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.

Víctor A Arrieta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.